biostudies-literatureUnknown10(12)Piotin MMedtronic<h4>Background and purpose</h4>Intrasaccular aneurysm flow disruption represents an emerging endovascular approach to treat intracranial aneurysms. The purpose of this study was to determine the clinical and angiographic outcomes of using the LUNA aneurysm embolization system (AES) for treatment of intracranial aneurysms.<h4>Materials and methods</h4>The LUNA AES Post-Market Clinical Follow-Up study is a prospective, multicenter, single-arm study that was designed to evaluate device safety and efficacy. Bifurcation and sidewall aneurysms were included. Aneurysm occlusion was assessed using the Raymond-Roy classification scale. Disability was assessed using the Modified Rankin Scale (mRS). Morbidity was defined as mRS >2 if baseline mRS ≤2, increase in mRS of 1 or more if baseline mRS >2, oJournal of neurointerventional surgerye34https://www.ebi.ac.uk/biostudies/studies/S-EPMC6288707biostudies-literatureThe LUNA aneurysm embolization system for intracranial aneurysm treatment: short-term, mid-term and long-term clinical and angiographic results.PMC6288707Anxionnat RSourour NGoffette PAndersson TPiotin MMounayer CJaworski MMangiafico SBiondi ASoderman MBlanc RfalseThe LUNA aneurysm embolization system for intracranial aneurysm treatment: short-term, mid-term and long-term clinical and angiographic results.<h4>Background and purpose</h4>Intrasaccular aneurysm flow disruption represents an emerging endovascular approach to treat intracranial aneurysms. The purpose of this study was to determine the clinical and angiographic outcomes of using the LUNA aneurysm embolization system (AES) for treatment of intracranial aneurysms.<h4>Materials and methods</h4>The LUNA AES Post-Market Clinical Follow-Up study is a prospective, multicenter, single-arm study that was designed to evaluate device safety and efficacy. Bifurcation and sidewall aneurysms were included. Aneurysm occlusion was assessed using the Raymond-Roy classification scale. Disability was assessed using the Modified Rankin Scale (mRS). Morbidity was defined as mRS >2 if baseline mRS ≤2, increase in mRS of 1 or more if baseline mRS >2, o2018-01-01T00:00:00Z2018 Dec2026-07-16T17:48:25.304Z2026-07-09T11:10:06.093ZS-EPMC62887072966985610.1136/neurintsurg-2018-013767